DorsaVi Ltd (ASX: DVL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

DorsaVi Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $8.95 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 596.66 million
Earnings per share -0.004
Dividend per share N/A
Year To Date Return 25.00%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • DorsaVi Ltd (ASX: DVL)
    Latest News

    a woman
    ⏸️ Investing

    Will Dorsavi Ltd be the next Catapult Group International Ltd?

    Dorsavi Ltd (ASX:DVL) sports some exciting potential.

    Read more »

    a woman
    ⏸️ Investing

    Are these the last 3 cheap stocks on the ASX?

    It might be time value investors took a closer look at Reject Shop Ltd (ASX:TRS), INGENIA STAPLED (ASX:INA) and Dorsavi…

    Read more »

    DVL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About DorsaVi Ltd

    DorsaVi Ltd is engaged in a distribution of innovative motion analysis technologies. It makes wearable sensors, software, and sophisticated algorithms that measure movement and muscle activation at around 200 frames per second. The company's products include ViSafe (Workplace), ViMove (Clinic), ViPerform (Elite Sports), and others. The firm operates in two segments: Clinical and Workplace. Its geographical segments are Australia, Europe, and the United States. The company generates the majority of its revenue from Clinical segment.

    DVL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    29 Feb 2024 $0.02 $0.00 0.00% 99,890 $0.02 $0.02 $0.02
    28 Feb 2024 $0.02 $0.00 0.00% 220 $0.01 $0.02 $0.01
    26 Feb 2024 $0.02 $0.00 0.00% 59,777 $0.02 $0.02 $0.02
    23 Feb 2024 $0.02 $0.00 0.00% 555,703 $0.01 $0.02 $0.01
    22 Feb 2024 $0.01 $0.00 0.00% 125,000 $0.02 $0.02 $0.01
    21 Feb 2024 $0.02 $0.00 0.00% 799,133 $0.02 $0.02 $0.01
    20 Feb 2024 $0.02 $0.00 0.00% 411,886 $0.02 $0.02 $0.02
    15 Feb 2024 $0.02 $0.00 0.00% 247,217 $0.02 $0.02 $0.02
    14 Feb 2024 $0.01 $0.00 0.00% 570,000 $0.01 $0.02 $0.01
    13 Feb 2024 $0.01 $0.00 0.00% 100,000 $0.01 $0.01 $0.01
    12 Feb 2024 $0.01 $0.00 0.00% 210,508 $0.01 $0.01 $0.01
    07 Feb 2024 $0.01 $0.00 0.00% 509,772 $0.01 $0.01 $0.01
    06 Feb 2024 $0.01 $0.00 0.00% 330,280 $0.01 $0.01 $0.01

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    06 Oct 2023 Michael Panaccio Issued 1,000,001 $11,000
    Issue of options.
    06 Oct 2023 Caroline Elliott Issued 1,000,001 $11,000
    Issue of options.
    06 Oct 2023 Ashraf Attia Issued 1,000,001 $11,000
    Issue of options.
    03 Jul 2023 Caroline Elliott Issued 1,000,001 $11,000
    Issue of options.
    03 Jul 2023 Ashraf Attia Issued 1,000,001 $11,000
    Issue of options.
    03 Jul 2023 Andrew Ronchi Issued 3,450,705 $43,000
    Director remuneration.
    03 Jul 2023 Andrew Ronchi Transfer 3,700,000 $48,100
    Off-market transfer.
    03 Jul 2023 Andrew Ronchi Transfer 3,700,000 $48,100
    Off-market transfer.
    03 Jul 2023 Michael Panaccio Issued 1,000,001 $11,000
    Issue of options.
    03 Apr 2023 Michael Panaccio Issued 733,334 $1,100
    Issue of options.
    03 Apr 2023 Caroline Elliott Issued 733,334 $1,100
    Issue of options.
    03 Apr 2023 Ashraf Attia Issued 733,334 $1,100
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Michael Panaccio Non-Executive DirectorInterim Chairman May 2008
    Mr Panaccio is one of the founding directors of Starfish Ventures Pty Ltd. He was formerly an Investment Manager with JAFCO Investment (Asia Pacific). Prior to joining JAFCO, Michael was Head of the Department of Molecular Biology at the Victorian Institute of Animal Sciences. Michael has previously been a director of technology businesses in Australia and the US including ImpediMed Ltd, SIRTeX Medical Ltd, Protagonist Therapeutic Inc and Energy Response Pty Ltd. He is Member of Risk Committee.
    Ms Caroline Ann Elliott Non-Executive Director Nov 2017
    Ms Elliott is currently a Director of the National Film and Sound Archive of Australia, St John's Ambulance Australia (Vic) and Wiltrust Nominees Pty Ltd. She has previously held non-executive director roles at Cell Therapies Pty Ltd, Peter MacCallum Cancer Centre and the Public Transport Ombudsman Limited. She is currently the Chief Executive Officer at apparel business, The Propel Group Pty Ltd, and was previously the CFO and Company Secretary at Optal Ltd. She is Chair of Risk Committee.
    Dr Andrew James Ronchi Chief Executive OfficerExecutive Director Feb 2008
    Dr Ronchi was a practising physiotherapist both at an AFL club and in private practice. He has also been founding partner in two physiotherapy centres, the largest of these employing 28 staff (including 13 physiotherapists).
    Mr Ashraf Attia Non-Executive Director Jul 2008
    Mr Attia has had senior management experience in multinational operations for over 30 years within the medical devices, biotechnology and diagnostics industries. He is currently Chief Executive Officer of Bionic Vision Technologies. Prior to Bionic Vision, Ash held the position of Vice President of Asia Pacific, Middle East and Israel at TransMedics Inc. He has held several senior executive roles with global medical devices organizations and has experience in the areas of commercialization, business development, clinical, regulatory, R&D, strategic marketing, sales and distribution management. He is Member of Risk Committee.
    Dr Michael Winlo Non-Executive Director Oct 2023
    Dr Winlo has a leadership experience across the biotechnology, pharmaceutical and technology sectors. He is currently Chief Executive Officer and Managing Director of Emyria Limited (ASX:EMD), a clinical drug development company, as well as a Non-Executive Director of Nanoveu Limited (ASX:NVU), a company specialising in protective films and coatings. Dr Winlo also serves as a Director and former CEO of Linear Clinical Research, a world-class provider of early and late-stage pharmaceutical trial facilities and management services. Prior to his role at Linear, Dr Winlo was based in Silicon Valley for five years as the Health Lead at Palantir Technologies (NYSE:PLTR).
    Mr Justin Mouchacca Company Secretary Sep 2023
    -
    Justin Mouchacca Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Mr Bilal Ahmad 53,100,000 9.54%
    Starfish Technology Fund Ii Nominees A Pty Ltd 48,763,230 8.76%
    Starfish Technology Fund Ii Nominees B Pty Ltd 48,763,229 8.76%
    Mr Sufian Ahmad <Sixty Two Capital A/C> 20,000,000 3.59%
    Ms Chunyan Niu 19,382,316 3.48%
    Mr Bin Liu 18,181,818 3.27%
    Vesparum Group Investments Pty Ltd 17,182,142 3.09%
    Mr Sufian Ahmad 17,100,000 3.07%
    Kobala Investments Pty Ltd <Fernando Edward Family A/C> 15,000,000 2.69%
    Tanarny Super Fund Pty Ltd <Tanarny Super Fund A/C> 14,209,132 2.55%
    Ddpevcic (Wa) Pty Ltd <Dominic Family A/C> 12,590,909 2.26%
    Clayton Capital Pty Ltd 12,590,909 2.26%
    449 Investments Pty Ltd <The A&R Hynes Family S/F A/C> 10,429,167 1.87%
    Mr Salvatore Di Vincenzo 8,517,332 1.53%
    Glenbarry Pty Ltd <Thomas A Hutchins Family A/C> 8,333,333 1.50%
    Ar Bsm Pty Ltd <Ar Bsm A/C> 7,606,965 1.37%
    Valence Holdings Pty Ltd The Pw & Cm Stinton <Superannuation Fund A/C> 5,688,006 1.02%
    Mr Brendan Thomas Case 5,060,240 0.91%
    Dr Zonair Ikram 4,534,722 0.81%
    Creative Hindsight Pty Ltd 4,244,417 0.76%

    Profile

    since

    Note